From pharmaceutical critical care manufacturing and packaging paper mills to chemical processing plants — Optimal delivers OEE monitoring, ISO 55001-aligned asset management and structured maintenance strategy that protects both production throughput and regulatory compliance.
Chemical and pharmaceutical manufacturers operate at the intersection of two unforgiving constraints: regulatory compliance that demands traceability, defensibility and documented maintenance governance — and production economics that demand maximum throughput, minimum unplanned downtime, and measurable OEE across every shift.
The organisations that manage this intersection well are not those with the strictest quality culture alone — they are those with structured asset management systems that make compliance and performance reinforce each other, not compete.
How ARaaS® solves thisIn process manufacturing, the first discipline is seeing clearly. Optimal deploys Optimal360™ real-time OEE monitoring to provide shift-by-shift visibility across production lines — automatically capturing downtime causes, production rates and quality deviations without burdening operators with manual logging.
That data foundation then enables structured reliability decisions: FMECA-based maintenance strategies aligned to equipment criticality, SAP or Maximo-ready work packages, and an asset management system that satisfies both GMP auditors and production directors.
"In pharmaceutical and chemical manufacturing, the audit will always come. The question is whether your maintenance system is something you explain — or something you stand behind."
Optimal · Asset Performance ManagementOptimal deploys Optimal360™ — our IIoT-enabled OEE monitoring platform — across pharmaceutical and process manufacturing environments. The plug-and-play approach requires no complex integration: sensors are fitted to production lines and live OEE data is visible on the shop floor and in management dashboards within days. For manufacturers operating under GMP and PIC/S requirements, automated data capture removes manual logging risk and provides auditable, timestamped production records aligned to regulatory documentation standards.
OEE monitoring, maintenance strategy, ISO 55001 governance and process plant reliability — integrated from production line to asset management system.
For multinational chemical and pharmaceutical groups, ISO 55001 is no longer aspirational — it is a corporate governance requirement. Optimal's gap assessment and roadmap methodology provides the structured, evidence-based pathway from current state to certified system.
The process involves site audit, senior management workshops, operational team engagement and a clause-by-clause assessment against ISO 55001:2014 — producing a board-ready report with specific observations, maturity scoring and a prioritised improvement roadmap that is realistic to implement.
Optimal has delivered structured asset performance and digital programmes for some of Southern Africa's most recognised pharmaceutical and packaging manufacturers — including:
Detailed case studies below are anonymised in line with Optimal's client confidentiality policy. Contact us to arrange reference calls with relevant operators.
A leading JSE-listed pharmaceutical manufacturer operating Africa's only integrated medical grade plastics and pharmaceutical manufacturing facility — producing intravenous fluids, blood bags, renal dialysis products and large and small-volume parenterals across three Gauteng facilities. High-volume, highly automated lines operating under PIC/S and South African MCC standards, with no real-time visibility into production losses, unplanned downtime causes or shift-by-shift OEE performance. Manual tracking processes were inadequate for the pace and precision requirements of the operation.
A large-scale global manufacturing group with multiple production sites across Europe, Africa and the Americas requiring a formal, group-wide asset management system to align operations across diverse geographies and manufacturing technologies. Corporate leadership required ISO 55001 governance maturity for investor and board reporting, with no structured pathway established at site level.
Process plant operating with no structured asset hierarchy and a CMMS populated with equipment descriptions that were inconsistent, incomplete and impossible to use for meaningful maintenance analysis. Time-based PM schedules driving over-maintenance on non-critical equipment while critical failure modes were unaddressed.
Pharmaceutical manufacturer with multiple production facilities reporting OEE using different manual methods — inconsistent definitions, no common downtime coding, no ability to benchmark across sites or identify which plants were performing best and why.
High-speed packaging and converting lines with recurring unplanned failures on critical rotating equipment — drive motors, conveyors and sealing systems. No condition monitoring in place. Reactive maintenance consuming budget and creating production plan disruption on high-value lines.
GARPI™ is the first independent, ISO 55001-aligned global benchmark of asset performance management. For chemical and pharmaceutical manufacturers, it provides objective evidence of where your organisation sits across eight reliability dimensions — from maintenance strategy maturity and data quality to workforce capability and lifecycle financial alignment. Understand your gaps. Close them before the auditor does.